Anthera Pharmaceuticals Inc (ANTH) was Initiated by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $10. H.C. Wainwright advised their investors in a research report released on Jul 8, 2016.
Anthera Pharmaceuticals Inc opened for trading at $3.18 and hit $3.25 on the upside on Tuesday, eventually ending the session at $3.24, with a gain of 1.89% or 0.06 points. The heightened volatility saw the trading volume jump to 2,63,848 shares. Company has a market cap of $133 M.
In a different news, on Nov 18, 2015, Colin Hislop (Chief Medical Officer) sold 12,500 shares at $5.31 per share price. According to the SEC, on Oct 13, 2015, Debra Odink (Chief Technology Officer) sold 1,205 shares at $6.15 per share price.
Anthera Pharmaceuticals Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company’s primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others. The Company’s second product candidate Sollpura (liprotamase) is a Phase III investigational pancreatic enzyme replacement therapy (PERT) intended for the treatment of patients with exocrine pancreatic insufficiency (EPI) often seen in patients with cystic fibrosis and other conditions.